Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | ESR1 | P03372 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | ATM | Q13315 | 2/20 | 0.81 |
| ▸ | PGR | P06401 | 2/20 | 0.81 |
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.74 |
| ▸ | SHBG | P04278 | 2/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.74 |
| ▸ | HTR2B | P41595 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28792822 | 0.91 | LMNA (0.86) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL10201260 | 0.90 | ESR1 (1.00) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL13712636 | 0.90 | ESR1 (1.00) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL20874461 | 0.90 | ESR1 (1.00) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL2099105 | 0.90 | ESR1 (1.00) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL148561 | 0.90 | ESR1 (1.00) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL28792824 | 0.90 | ESR1 (0.88) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL29575955 | 0.90 | ESR1 (1.00) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL9273489 | 0.89 | LMNA (0.83) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL6862943 | 0.88 | MAPT (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772878-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | DEKK-TEC, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-9422241-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | DEKK-TEC, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| US-20120177634-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | DEKK-TEC, INC. | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772878-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | MCL1, DNMT1, MYC | LMNA 1636/4885ESR1 2112/4885SMN1; SMN2 1513/4885 |
| US-20120177634-A1 | DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS | MCL1, DNMT1, MYC | LMNA 1636/4885ESR1 2112/4885SMN1; SMN2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.